The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Alnylam Pharmaceuticals Inc shares valued at $666,987 were sold by Garg Pushkal on Aug 19 ’25. At $458.41 per share, Garg Pushkal sold 1,455 shares. The insider’s holdings dropped to 20,221 shares worth approximately $9.45 million following the completion of this transaction.
Also, Garg Pushkal sold 1,396 shares, netting a total of over 632,759 in proceeds. Following the sale of shares at $453.27 each, the insider now holds 21,676 shares.
Before that, Tanguler Tolga had sold 1,396 shares from its account. In a trade valued at $632,759, the EVP, Chief Commercial Officer traded Alnylam Pharmaceuticals Inc shares for $453.27 each. Upon closing the transaction, the insider’s holdings decreased to 1,396 shares, worth approximately $13.78 million.
As published in a research note from Wolfe Research on August 04, 2025, Alnylam Pharmaceuticals Inc [ALNY] has been rated up from an Underperform to a Peer perform. Analysts at Oppenheimer upgraded the stock from ‘”a Perform”‘ to ‘”an Outperform”‘ outlook in a report released in early August. Earlier on July 21, 2025, Truist initiated its rating. Their recommendation was “a Buy” for ALNY stock.
Analyzing ALNY Stock Performance
On last trading session, Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] rose 2.02% to $467.55. The stock’s lowest price that day was $454.68, but it reached a high of $467.71 in the same session. During the last five days, there has been a surge of approximately 5.61%. Over the course of the year, Alnylam Pharmaceuticals Inc shares have jumped approximately 70.34%. Shares of the company reached a 52-week high of $467.71 on 08/21/25 and a 52-week low of $205.87 on 04/09/25.
Support And Resistance Levels for Alnylam Pharmaceuticals Inc (ALNY)
According to the 24-hour chart, there is a support level at 458.92, which, if violated, would cause prices to drop to 450.28. In the upper region, resistance lies at 471.95. The next price resistance is at 476.34. RSI (Relative Strength Index) is 87.31 on the 14-day chart, showing overbought technical sentiment.
Is Alnylam Pharmaceuticals Inc subject to short interest?
Stocks of Alnylam Pharmaceuticals Inc saw a sharp steep in short interest on 2025-07-31 dropping by 88854.0 shares to 3.24 million. Data from Yahoo Finance shows that the short interest on 2025-06-30 was 3.33 million shares. A decline of -2.74% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.08 of the overall float, the days-to-cover ratio (short ratio) decline to 3.08.
Which companies own the most shares of Alnylam Pharmaceuticals Inc (ALNY)?
In terms of Alnylam Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 365 in the next 12 months, down nearly -20.36% from the previous closing price of $458.31. Analysts anticipate Alnylam Pharmaceuticals Inc stock to reach 385 by 2025, with the lowest price target being 338. In spite of this, 20 analysts ranked Alnylam Pharmaceuticals Inc stock as Buy at the end of 2025. On March 31, 2025, Redburn Atlantic assigned a price target of “a Buy” to the stock and initiated coverage with a $353.
